182 related articles for article (PubMed ID: 7545222)
21. Cost-effectiveness of second-line chemotherapy for non-small cell lung cancer: an economic, randomized, prospective, multicenter phase III trial comparing docetaxel and pemetrexed: the GFPC 05-06 study.
Vergnenegre A; Corre R; Berard H; Paillotin D; Dujon C; Robinet G; Crequit J; Bota S; Thomas P; Chouaid C;
J Thorac Oncol; 2011 Jan; 6(1):161-8. PubMed ID: 21150465
[TBL] [Abstract][Full Text] [Related]
22. Gefitinib for the first-line treatment of locally advanced or metastatic non-small cell lung cancer.
Brown T; Boland A; Bagust A; Oyee J; Hockenhull J; Dundar Y; Dickson R; Ramani VS; Proudlove C
Health Technol Assess; 2010 Oct; 14(Suppl. 2):71-9. PubMed ID: 21047494
[TBL] [Abstract][Full Text] [Related]
23. Economic evaluation of a randomized clinical trial comparing vinorelbine, vinorelbine plus cisplatin, and vindesine plus cisplatin for non-small-cell lung cancer.
Smith TJ; Hillner BE; Neighbors DM; McSorley PA; Le Chevalier T
J Clin Oncol; 1995 Sep; 13(9):2166-73. PubMed ID: 7666075
[TBL] [Abstract][Full Text] [Related]
24. The project data sphere initiative: accelerating cancer research by sharing data.
Green AK; Reeder-Hayes KE; Corty RW; Basch E; Milowsky MI; Dusetzina SB; Bennett AV; Wood WA
Oncologist; 2015 May; 20(5):464-e20. PubMed ID: 25876994
[TBL] [Abstract][Full Text] [Related]
25. Cost-effectiveness analysis of three regimens using vinorelbine (Navelbine) for non-small cell lung cancer.
Hillner BE; Smith TJ
Semin Oncol; 1996 Apr; 23(2 Suppl 5):25-30. PubMed ID: 8610234
[TBL] [Abstract][Full Text] [Related]
26. Evaluating the financial impact of clinical trials in oncology: results from a pilot study from the Association of American Cancer Institutes/Northwestern University clinical trials costs and charges project.
Bennett CL; Stinson TJ; Vogel V; Robertson L; Leedy D; O'Brien P; Hobbs J; Sutton T; Ruckdeschel JC; Chirikos TN; Weiner RS; Ramsey MM; Wicha MS
J Clin Oncol; 2000 Aug; 18(15):2805-10. PubMed ID: 10920127
[TBL] [Abstract][Full Text] [Related]
27. Economic issues in defining stable funding levels for HIV/AIDS research.
Eastaugh SR
J Health Adm Educ; 1992; 10(1):139-49. PubMed ID: 10118035
[No Abstract] [Full Text] [Related]
28. How much is life worth: cetuximab, non-small cell lung cancer, and the $440 billion question.
Fojo T; Grady C
J Natl Cancer Inst; 2009 Aug; 101(15):1044-8. PubMed ID: 19564563
[TBL] [Abstract][Full Text] [Related]
29. Cost-effectiveness models of clinical trials of new pharmaceuticals for AIDS-related Pneumocystis carinii pneumonia: are they helpful to policy makers?
Bennett CL; Oddone E; Matchar D
Clin Perform Qual Health Care; 1995; 3(3):156-64. PubMed ID: 10151167
[TBL] [Abstract][Full Text] [Related]
30. American Society of Clinical Oncology guidance statement: the cost of cancer care.
Meropol NJ; Schrag D; Smith TJ; Mulvey TM; Langdon RM; Blum D; Ubel PA; Schnipper LE;
J Clin Oncol; 2009 Aug; 27(23):3868-74. PubMed ID: 19581533
[TBL] [Abstract][Full Text] [Related]
31. Economic analysis during phase III clinical trials: who, what, when, where, and why?
Bennett CL; Westerman IL
Oncology (Williston Park); 1995 Nov; 9(11 Suppl):169-75. PubMed ID: 8608049
[TBL] [Abstract][Full Text] [Related]
32. Accrual to National Cancer Institute-sponsored non-small-cell lung cancer trials: insights and contributions from the CCOP program.
Lyss AP; Lilenbaum RC
Clin Lung Cancer; 2009 Nov; 10(6):410-3. PubMed ID: 19900858
[TBL] [Abstract][Full Text] [Related]
33. Funding impact of the National Cancer Act and beyond.
Kalberer JT; Newell GR
Cancer Res; 1979 Oct; 39(10):4274-84. PubMed ID: 383282
[TBL] [Abstract][Full Text] [Related]
34. Incremental treatment costs in national cancer institute-sponsored clinical trials.
Goldman DP; Berry SH; McCabe MS; Kilgore ML; Potosky AL; Schoenbaum ML; Schonlau M; Weeks JC; Kaplan R; Escarce JJ
JAMA; 2003 Jun; 289(22):2970-7. PubMed ID: 12799405
[TBL] [Abstract][Full Text] [Related]
35. Impact of clinical trial protocols on patient care systems at the University of Texas M.D. Anderson Cancer Center.
Huber SL
Cancer; 1993 Nov; 72(9 Suppl):2824-7. PubMed ID: 8402512
[TBL] [Abstract][Full Text] [Related]
36. Potential evaluation of the incremental cost-effectiveness of paclitaxel in advanced non-small-cell lung cancer (Eastern Cooperative Oncology Group 5592).
Hillner BE
J Natl Cancer Inst Monogr; 1995; (19):65-7. PubMed ID: 7577209
[No Abstract] [Full Text] [Related]
37. Erlotinib for the treatment of relapsed non-small cell lung cancer.
McLeod C; Bagust A; Boland A; Hockenhull J; Dundar Y; Proudlove C; Davis H; Green J; Macbeth F; Stevenson J; Walley T; Dickson R
Health Technol Assess; 2009 Jun; 13 Suppl 1():41-7. PubMed ID: 19567213
[TBL] [Abstract][Full Text] [Related]
38. Measuring the incremental cost of clinical cancer research.
Goldman DP; Schoenbaum ML; Potosky AL; Weeks JC; Berry SH; Escarce JJ; Weidmer BA; Kilgore ML; Wagle N; Adams JL; Figlin RA; Lewis JH; Cohen J; Kaplan R; McCabe M
J Clin Oncol; 2001 Jan; 19(1):105-10. PubMed ID: 11134202
[TBL] [Abstract][Full Text] [Related]
39. Cost-effectiveness of pemetrexed plus cisplatin as first-line therapy for advanced nonsquamous non-small cell lung cancer.
Klein R; Muehlenbein C; Liepa AM; Babineaux S; Wielage R; Schwartzberg L
J Thorac Oncol; 2009 Nov; 4(11):1404-14. PubMed ID: 19786904
[TBL] [Abstract][Full Text] [Related]
40. Clinical trials: are they a good buy?
Bennett CL; Adams JR; Knox KS; Kelahan AM; Silver SM; Bailes JS
J Clin Oncol; 2001 Dec; 19(23):4330-9. PubMed ID: 11731516
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
